Kwan Soo Byun Selected Research

clevudine

7/2014	A randomized, open-label study comparing low-dose clevudine plus adefovir combination therapy with clevudine monotherapy in naïve chronic hepatitis B patients.
11/2011	Comparison of clevudine and entecavir for treatment-naive patients with chronic hepatitis B virus infection: two-year follow-up data.
3/2011	Clevudine-induced viral response, associated with continued reduction of HBsAg titer, was durable after the withdrawal of therapy.
10/2007	Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression.
5/2007	Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B.
1/2007	Clevudine therapy for 24 weeks further reduced serum hepatitis B virus DNA levels and increased ALT normalization rates without emergence of viral breakthrough than 12 weeks of clevudine therapy.
5/2006	A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kwan Soo Byun Research Topics

Disease

36	Chronic Hepatitis B 04/2021 - 12/2002
22	Hepatocellular Carcinoma (Hepatoma) 07/2021 - 08/2002
19	Fibrosis (Cirrhosis) 01/2022 - 10/2007
16	Liver Cirrhosis (Hepatic Cirrhosis) 01/2022 - 09/2003
12	Neoplasms (Cancer) 03/2021 - 01/2005
9	Infections 04/2017 - 12/2003
6	Non-alcoholic Fatty Liver Disease 04/2022 - 07/2004
6	Hepatitis B 01/2022 - 01/2008
6	End Stage Liver Disease 01/2021 - 08/2007
6	Chronic Hepatitis C 01/2015 - 12/2004
5	Disease Progression 01/2017 - 12/2002
5	Hemorrhage 12/2016 - 10/2007
4	Liver Diseases (Liver Disease) 01/2021 - 09/2003
4	Acute Kidney Injury (Acute Renal Failure) 05/2020 - 11/2013
4	Hepatitis 01/2014 - 03/2008
3	Neoplasm Metastasis (Metastasis) 03/2021 - 06/2002
3	Inflammation (Inflammations) 01/2021 - 12/2015
3	Esophageal and Gastric Varices (Esophageal Varices) 12/2016 - 08/2010
3	Gallstones (Gallstone) 06/2010 - 10/2003
2	Thrombosis (Thrombus) 03/2021 - 12/2017
2	Brain Diseases (Brain Disorder) 05/2020 - 02/2018
2	Ascites 02/2018 - 11/2009
2	Hepatic Encephalopathy 02/2018 - 01/2014
2	Neoplasms, Cystic, Mucinous, and Serous 02/2017 - 01/2006
2	Varicose Veins (Varicose Vein) 12/2016 - 01/2016
2	Viremia 11/2014 - 12/2009
2	Pyloric Stenosis 07/2013 - 06/2011
2	Pathologic Constriction (Stenosis) 07/2013 - 06/2011
2	Pain (Aches) 06/2012 - 06/2002
2	Nausea 06/2012 - 03/2008
2	Lymphatic Metastasis 04/2012 - 03/2007
1	Body Weight (Weight, Body) 01/2022
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 07/2021
1	Liver Neoplasms (Liver Cancer) 06/2021
1	Peritonitis 05/2020
1	Chronic Disease (Chronic Diseases) 05/2020

Drug/Important Bio-Agent (IBA)

22	Antiviral Agents (Antivirals)IBA 01/2022 - 12/2003
15	entecavir FDA Link 01/2022 - 01/2009
15	Hepatitis B e AntigensIBA 12/2017 - 12/2002
14	Lamivudine (Epivir)FDA Link 12/2017 - 12/2002
9	Tenofovir (Viread)FDA Link 01/2022 - 07/2008
9	adefovirIBA 01/2019 - 08/2007
7	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2017 - 09/2007
7	clevudineIBA 07/2014 - 05/2006
6	Biomarkers (Surrogate Marker)IBA 04/2022 - 01/2014
5	DNA (Deoxyribonucleic Acid)IBA 01/2017 - 03/2011
4	CholesterolIBA 01/2022 - 10/2003
4	Pharmaceutical PreparationsIBA 01/2022 - 01/2016
4	Sorafenib (BAY 43-9006)FDA Link 03/2021 - 03/2014
4	BilirubinIBA 01/2021 - 06/2002
4	MicroRNAs (MicroRNA)IBA 01/2021 - 01/2017
4	Ribavirin (Virazole)FDA LinkGeneric 03/2013 - 12/2004
3	alpha-Fetoproteins (alpha-Fetoprotein)IBA 07/2021 - 04/2019
3	InterferonsIBA 06/2021 - 09/2007
3	Alanine Transaminase (SGPT)IBA 04/2021 - 03/2011
3	Indicators and Reagents (Reagents)IBA 01/2020 - 09/2016
3	SodiumIBA 02/2018 - 08/2007
3	AntigensIBA 09/2016 - 03/2011
3	Fatty Acids (Saturated Fatty Acids)IBA 12/2015 - 07/2004
3	Cytidine Triphosphate (CTP)IBA 04/2012 - 08/2007
3	Matrix Metalloproteinases (MMPs)IBA 03/2007 - 09/2003
2	Simvastatin (Zocor)FDA LinkGeneric 01/2022 - 06/2014
2	N- (2- cyclohexyloxy- 4- nitrophenyl)methanesulfonamideIBA 01/2022 - 06/2014
2	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 01/2022 - 06/2014
2	Tumor Biomarkers (Tumor Markers)IBA 07/2021 - 03/2014
2	Proteins (Proteins, Gene)FDA Link 07/2021 - 01/2020
2	Cystatin CIBA 01/2019 - 11/2009
2	CreatinineIBA 01/2019 - 11/2009
2	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 12/2015 - 01/2008
2	acarboxyprothrombin (PIVKA)IBA 03/2015 - 03/2014
2	Interferon-alpha (Interferon Alfa)IBA 01/2015 - 12/2004
2	EnzymesIBA 03/2014 - 01/2008
2	Anti-Bacterial Agents (Antibiotics)IBA 09/2012 - 03/2009
2	adefovir dipivoxil (Hepsera)FDA Link 09/2010 - 08/2007
2	PPAR alphaIBA 01/2008 - 07/2004
2	Viral DNAIBA 12/2006 - 12/2003
2	ErbB Receptors (EGF Receptor)IBA 01/2005 - 10/2003
1	HDL CholesterolIBA 01/2022
1	Drinking WaterIBA 01/2022
1	Thioacetamide (Thioacetamid)IBA 01/2022
1	LDL Lipoproteins (beta Lipoproteins)IBA 01/2022
1	tenofovir alafenamideIBA 01/2022
1	CollagenIBA 01/2022
1	lentil lectinIBA 07/2021
1	milk fat globuleIBA 07/2021
1	Factor VIII (Coagulation Factor VIII)IBA 07/2021
1	Epidermal Growth Factor (EGF)IBA 07/2021
1	thiamine triphosphorate (TTP)IBA 03/2021
1	Messenger RNA (mRNA)IBA 01/2021
1	nasIBA 01/2021
1	25-hydroxyvitamin DIBA 05/2020

Therapy/Procedure

32	Therapeutics 01/2022 - 08/2002
3	Drug Therapy (Chemotherapy) 03/2021 - 08/2002
3	Liver Transplantation 01/2021 - 03/2010
3	Stents 07/2013 - 07/2006
2	Aftercare (After-Treatment) 01/2021 - 04/2012
2	Ligation 12/2016 - 01/2016
2	Sclerotherapy 12/2016 - 01/2016
2	Self Expandable Metallic Stents 07/2013 - 06/2011
2	Gastrectomy 04/2012 - 06/2011